NBIX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NB

Mkt Cap

$13.80B

Volume

625.29K

Next Earnings

October 27th

Loading chart

NB

NBIXNeurocrine Biosciences Inc

NBIX

Pay with—

Available Balance0.00

NB

Mkt Cap

$13.79B

Volume

625.29K

Next Earnings

October 27th

Chart Financials Earnings News About Insider Filings

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsightOver 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.GlobeNewswire Inc. · Oct 15, 2026

Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-TermNeurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top value stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company features an attractive forward P/E ratio of 14.86, a Value Style Score of B, and has seen upward earnings estimate revisions with a consensus estimate of $9.09 per share for fiscal 2026, along with an average earnings surprise of +13.6%.Zacks Investment Research · Oct 14, 2026

NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?A comparison of two Medical-Drugs sector stocks reveals that Neurocrine Biosciences (NBIX) presents a better value opportunity than Sandoz Group AG (SDZNY). Both stocks hold a Zacks Rank #2 (Buy) with positive earnings outlooks, but NBIX's superior valuation metrics—including a lower forward P/E ratio of 15.55 versus SDZNY's 20.49, and a PEG ratio of 0.53 compared to 1.69—earned it a Value grade of B versus SDZNY's C grade.Zacks Investment Research · Oct 13, 2026

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-TermNeurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top growth stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company is forecasting year-over-year earnings growth of 42.3% for fiscal 2026, with a consensus earnings estimate of $9.09 per share and an average earnings surprise of +13.6%.Zacks Investment Research · Oct 13, 2026

4 CNS Drug Stocks Worth Watching This World Mental Health DayFour central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders.Zacks Investment Research · Oct 9, 2026

Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's CognitionNeurocrine Biosciences has received FDA IND acceptance for a Phase 2 study of NBI-1117567, an oral muscarinic M1/M4 selective agonist for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment. This marks the third compound in Nxera's muscarinic agonist portfolio to advance to Phase 2, following direclidine in Phase 3 and NBI-1117570 in Phase 2.GlobeNewswire Inc. · Aug 26, 2026

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026Nxera Pharma reported strong Q2 2026 results with revenue of JPY 18.9 billion, up from the prior year, driven by eight R&D milestone events. The company achieved key regulatory designations for vamorolone in South Korea, progressed partnered programs with Neurocrine, Lilly, and AbbVie, and benefited from Lilly's acquisition of Centessa Pharmaceuticals. Operating profit turned positive at JPY 1.9 billion versus a prior loss, with core operating profit reaching JPY 6.5 billion.GlobeNewswire Inc. · Aug 7, 2026

Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New BuysFundstrat Capital completed its May 2026 quarterly rebalance of the Fundstrat Granny Shots US Small- & Mid-Cap ETF (GRNJ), adding 10 stocks including First Solar, Zoom, Credo Technology, and Neurocrine Biosciences, while removing 8 positions. CIO Tom Lee positions the portfolio for a 'challenging but ultimately constructive' environment, with the strategy focusing on companies benefiting from structural tailwinds across themes like Millennials, Global Labor Supply, Energy, Cybersecurity, and Easing Financial Conditions.Benzinga · Jun 10, 2026

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026Nxera Pharma reported strong Q1 2026 results with revenue of JPY 11.3 billion, a significant increase from the prior year, driven by seven R&D milestone events. The company signed a licensing agreement with Santhera for vamorolone in APAC markets, achieved positive Phase 3 results for daridorexant in South Korea, and received milestone payments from Neurocrine and AbbVie. Additionally, Centessa Pharmaceuticals (spun out from Nxera in 2019) agreed to be acquired by Eli Lilly for up to $7.8 billion, with Nxera retaining rights to milestone and royalty payments.GlobeNewswire Inc. · May 1, 2026

Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with SchizophreniaNeurocrine Biosciences has initiated a Phase 2 clinical trial of NBI-1117570, a dual muscarinic M1/M4 receptor agonist discovered by Nxera Pharma, for treating schizophrenia. Nxera will receive $22.5 million in milestone payments from Neurocrine as a result of this achievement.GlobeNewswire Inc. · Apr 12, 2026

to start trading

NB

NBIXNeurocrine Biosciences Inc

NBIX

Pay with—

Available Balance0.00

Your PositionYou don't own any NBIX yet.

Related Tickers

Earnings